Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis
- PMID: 27599725
- DOI: 10.1136/bmj.i4482
Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis
Abstract
Objective: To quantify the association between atrial fibrillation and cardiovascular disease, renal disease, and death.
Design: Systematic review and meta-analysis.
Data sources: Medline and Embase.
Eligibility criteria: Cohort studies examining the association between atrial fibrillation and cardiovascular disease, renal disease, and death. Two reviewers independently extracted study characteristics and the relative risk of outcomes associated with atrial fibrillation: specifically, all cause mortality, cardiovascular mortality, major cardiovascular events, any stroke, ischaemic stroke, haemorrhagic stroke, ischaemic heart disease, sudden cardiac death, congestive heart failure, chronic kidney disease, and peripheral arterial disease. Estimates were pooled with inverse variance weighted random effects meta-analysis.
Results: 104 eligible cohort studies involving 9 686 513 participants (587 867 with atrial fibrillation) were identified. Atrial fibrillation was associated with an increased risk of all cause mortality (relative risk 1.46, 95% confidence interval 1.39 to 1.54), cardiovascular mortality (2.03, 1.79 to 2.30), major cardiovascular events (1.96, 1.53 to 2.51), stroke (2.42, 2.17 to 2.71), ischaemic stroke (2.33, 1.84 to 2.94), ischaemic heart disease (1.61, 1.38 to 1.87), sudden cardiac death (1.88, 1.36 to 2.60), heart failure (4.99, 3.04 to 8.22), chronic kidney disease (1.64, 1.41 to 1.91), and peripheral arterial disease (1.31, 1.19 to 1.45) but not haemorrhagic stroke (2.00, 0.67 to 5.96). Among the outcomes examined, the highest absolute risk increase was for heart failure. Associations between atrial fibrillation and included outcomes were broadly consistent across subgroups and in sensitivity analyses.
Conclusions: Atrial fibrillation is associated with an increased risk of death and an increased risk of cardiovascular and renal disease. Interventions aimed at reducing outcomes beyond stroke are warranted in patients with atrial fibrillation.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Comment in
-
Atrial Fibrillation Increases Risk of CVD, Renal Disease, Death.Am J Nurs. 2017 Apr;117(4):66. doi: 10.1097/01.NAJ.0000515238.82289.81. Am J Nurs. 2017. PMID: 28333749 No abstract available.
Similar articles
-
Atrial fibrillation as risk factor for cardiovascular disease and death in women compared with men: systematic review and meta-analysis of cohort studies.BMJ. 2016 Jan 19;532:h7013. doi: 10.1136/bmj.h7013. BMJ. 2016. PMID: 26786546 Free PMC article. Review.
-
Cardiovascular Events after New-Onset Atrial Fibrillation in Adults with CKD: Results from the Chronic Renal Insufficiency Cohort (CRIC) Study.J Am Soc Nephrol. 2018 Dec;29(12):2859-2869. doi: 10.1681/ASN.2018050514. Epub 2018 Oct 30. J Am Soc Nephrol. 2018. PMID: 30377231 Free PMC article.
-
Causes of Death and Influencing Factors in Patients with Atrial Fibrillation.Am J Med. 2016 Dec;129(12):1278-1287. doi: 10.1016/j.amjmed.2016.06.045. Epub 2016 Jul 28. Am J Med. 2016. PMID: 27476087
-
Atrial fibrillation and the risk for myocardial infarction, all-cause mortality and heart failure: A systematic review and meta-analysis.Eur J Prev Cardiol. 2017 Sep;24(14):1555-1566. doi: 10.1177/2047487317715769. Epub 2017 Jun 15. Eur J Prev Cardiol. 2017. PMID: 28617620 Free PMC article. Review.
-
Atrial fibrillation is associated with sudden cardiac death: a systematic review and meta-analysis.J Interv Card Electrophysiol. 2018 Mar;51(2):91-104. doi: 10.1007/s10840-017-0308-9. Epub 2018 Jan 13. J Interv Card Electrophysiol. 2018. PMID: 29332241 Review.
Cited by
-
Bleeding Complications of Anticoagulation Therapy in Clinical Practice-Epidemiology and Management: Review of the Literature.Biomedicines. 2024 Oct 1;12(10):2242. doi: 10.3390/biomedicines12102242. Biomedicines. 2024. PMID: 39457555 Free PMC article. Review.
-
Inflammation in liver fibrosis and atrial fibrillation: A prospective population-based proteomic study.JHEP Rep. 2024 Jul 18;6(10):101171. doi: 10.1016/j.jhepr.2024.101171. eCollection 2024 Oct. JHEP Rep. 2024. PMID: 39380717 Free PMC article.
-
Global burden of atrial fibrillation attributable to high body mass index from 1990 to 2021: findings from the Global Burden of Disease Study 2021.BMC Cardiovasc Disord. 2024 Oct 8;24(1):542. doi: 10.1186/s12872-024-04202-5. BMC Cardiovasc Disord. 2024. PMID: 39379831 Free PMC article.
-
A comparative study of the clinical benefits of rivaroxaban and dabigatran in patients with nonvalvular atrial fibrillation with high bleeding risk.Front Cardiovasc Med. 2024 Sep 17;11:1445970. doi: 10.3389/fcvm.2024.1445970. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 39359641 Free PMC article.
-
The burden of atrial fibrillation in the Asia-Pacific region.Nat Rev Cardiol. 2024 Dec;21(12):841-843. doi: 10.1038/s41569-024-01091-1. Nat Rev Cardiol. 2024. PMID: 39322762 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical